Related references
Note: Only part of the references are listed.Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma
Mingyu Zhu et al.
TRANSLATIONAL CANCER RESEARCH (2022)
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
Tiuri E. Kroese et al.
EUROPEAN JOURNAL OF CANCER (2022)
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara et al.
NATURE (2022)
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Changsong Qi et al.
NATURE MEDICINE (2022)
HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
J. Tabernero et al.
ANNALS OF ONCOLOGY (2022)
Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses
Ruiyi Deng et al.
FRONTIERS IN IMMUNOLOGY (2022)
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma The AIO INTEGA Randomized Clinical Trial
Alexander Stein et al.
JAMA ONCOLOGY (2022)
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥ 10
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2021)
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
Camille Evrard et al.
DIGESTIVE AND LIVER DISEASE (2021)
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
U. Sahin et al.
ANNALS OF ONCOLOGY (2021)
Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia
Deqiang Wang et al.
GASTRIC CANCER (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
Helicobacter pylori in gastric cancer: Features of infection and their correlations with long-term results of treatment
Marina A. Senchukova et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2021)
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
F. Pietrantonio et al.
ESMO OPEN (2021)
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
Josep Tabernero et al.
FUTURE ONCOLOGY (2021)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
Angela Dalia Ricci et al.
CANCERS (2021)
Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
S-E. Al-Batran et al.
ANNALS OF ONCOLOGY (2021)
Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A
D. V. Catenacci et al.
ANNALS OF ONCOLOGY (2021)
Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
J. Xu et al.
ANNALS OF ONCOLOGY (2021)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun et al.
LANCET (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
Xiaoqiao Liu et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y. Janjigian et al.
LANCET ONCOLOGY (2020)
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO
C. Pauligk et al.
ANNALS OF ONCOLOGY (2020)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial
Daniel V. T. Catenacci et al.
LANCET ONCOLOGY (2020)
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells
Matthias Braun et al.
IMMUNITY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options
Valli De Re et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara et al.
LANCET ONCOLOGY (2019)
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2019)
Gender medicine and oncology: report and consensus of an ESMO workshop
A. D. Wagner et al.
ANNALS OF ONCOLOGY (2019)
836TiPGLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
M Shah et al.
ANNALS OF ONCOLOGY (2019)
198TiPSPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
K Yamaguchi et al.
ANNALS OF ONCOLOGY (2019)
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N. Boku et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Y. -J. Bang et al.
ANNALS OF ONCOLOGY (2018)
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2018)
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Yelena Y. Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)
Hiroshi Saeki et al.
EUROPEAN JOURNAL OF CANCER (2018)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda et al.
JNCI-Journal of the National Cancer Institute (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda et al.
JNCI-Journal of the National Cancer Institute (2017)
CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer
Weiling He et al.
CANCER RESEARCH (2017)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. C. Smyth et al.
ANNALS OF ONCOLOGY (2016)
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Lordick et al.
ANNALS OF ONCOLOGY (2016)
Sex differences in immune responses
Sabra L. Klein et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Share Paper
